Nature Reviews Drug Discovery contents March 2017 Volume 16 Number 3 pp 149-222

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
March 2017 Volume 16 Number 3		Advertisement
2015 2-year Impact Factor 47.120 Journal Metrics 2-year Median 31	In this issue Comment News and Analysis Research Highlights Focus on: RNA-based therapies Also this month Article series: RNA-based therapies  Featured article: Non-coding RNAs as drug targets Masayuki Matsui & David R. Corey	Genomics has met its match!  MEET METABOLON, GENOMICS' PERFECT COMPLEMENT Explore the relationship between genotype and phenotype with Metabolon's revolutionary solutions. We turn data into actionable insight unlocking the full potential of the genome. See why genomics and metabolomics are better together. Download our eBook
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Harrington drug discovery research grants - awards up to $700,000 Harrington Discovery Institute at University Hospitals in Cleveland, Ohio solicits proposals for the 2018 Harrington Scholar-Innovator Award, offering physician-scientists the resources to advance discoveries into medicines. Letters of Intent accepted through April 5, 2017. Apply now at HarringtonDiscovery.org/Grant.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Insight: Neurodegenerative Diseases  In this Insight experts discuss their current views on brain ageing and rejuvenation, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease and prion disease. It also provides a structural perspective on the properties of amyloids. Access the Insight free online Produced with support from  Eli Lilly and Company
Comment: Poor medication adherence in clinical trials: consequences and solutions Alasdair Breckenridge, Jeffrey K. Aronson, Terrence F. Blaschke, Dan Hartman, Carl C. Peck & Bernard Vrijens p149 | doi:10.1038/nrd.2017.1 Poor adherence to medicines in clinical trials can undermine the value of the trials; for example, by compromising estimates of the benefits and risks of a medicine. In this article, we highlight such consequences and also discuss approaches to tackle this problem. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Out-licensing role reversal Chris Morrison p151 | doi:10.1038/nrd.2017.35 An innovative alliance structure is the latest advance in pharma's externalization push. PDF
Bracing for the biosimilar wave Asher Mullard p152 | doi:10.1038/nrd.2017.36 The regulatory uncertainty around biosimilars in the United States is finally lifting, just months after the first biosimilar monoclonal antibody hit the US market. PDF
NEWS IN BRIEF BACE inhibitor bust in Alzheimer trial Asher Mullard p155 | doi:10.1038/nrd.2017.43 PDF
NEWS IN BRIEF New plaque psoriasis approval carries suicide warning Asher Mullard p155 | doi:10.1038/nrd.2017.44 PDF
NEWS IN BRIEF Biotech gender gap Asher Mullard p155 | doi:10.1038/nrd.2017.45 PDF
BIOBUSINESS BRIEFS Regulatory watch: The target product profile as a tool for regulatory communication: advantageous but underused Adria Tyndall, Wenny Du & Christopher D. Breder p156 | doi:10.1038/nrd.2016.264 PDF
BIOBUSINESS BRIEFS Trial watch: Clinical trial cycle times continue to increase despite industry efforts Linda Martin, Melissa Hutchens & Conrad Hawkins p157 | doi:10.1038/nrd.2017.21 PDF
AN AUDIENCE WITH Melinda Richter p158 | doi:10.1038/nrd.2017.41 Melinda Richter, head of JLABS at J&J Innovation, celebrates the fifth anniversary of a big pharma experiment with life science incubators. PDF
FROM THE ANALYST'S COUCH Biopharma deal-making in 2016 Amanda Micklus & Steven Muntner p161 | doi:10.1038/nrd.2017.15 This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2016, highlighting trends and major deals. PDF
RESEARCH HIGHLIGHTS Top Antifungals: JNK inhibitors boost antifungal immunity p163 | doi:10.1038/nrd.2017.29 PDF Ischaemic disorders: Safe path to thrombosis prevention p164 | doi:10.1038/nrd.2017.27 PDF Bone diseases: MST1R inhibitor prevents bone osteolysis p164 | doi:10.1038/nrd.2017.30 PDF Anticancer agents: Allosteric histone methyltransferase modulators block tumour growth p165 | doi:10.1038/nrd.2017.28 PDF Cancer: CD99 marks malignant myeloid stem cells p166 | doi:10.1038/nrd.2017.31 PDF IN BRIEF Alzheimer disease: Antisense oligonucleotide reverses tau pathology | Ocular disorders: Collagen IV-derived peptide prevents angiogenesis | Anticancer agents: Engineered platelets deliver immunotherapy | Atherosclerosis: Haematopoietic mutation promotes atherogenesis PDF Nature Reviews Drug Discovery JOBS of the week Experts in Drug Development : Mechelen, Belgium Galapagos Translational Medicine Leader (TML) (m/f) : Penzberg , Germany Roche Diagnostics GmbH Medicinal chemist : Krakow, Poland Selvita Senior Vice President for Research : Lubbock, TX, United States Texas Tech University Health Sciences Center Senior Scientist, Pharmacology : Massachusetts, MA, United States Celgene Corporation More Science jobs from Nature Reviews Drug Discovery EVENT 4th NovAliX Conference - Biophysics in Drug Discovery 2017 06.06.17 Strasbourg, France More science events from
Advertisement
Rapid, Reproducible Protein Separations Shimadzu's Perfinity Workstation provides a seamlessly integrated solution for affinity enrichment and protein digestion. It offers serum to purified peptides in as little as 10 minutes, reduces a three day workflow to less than one hour, and offers high-quality, reproducible proteolysis data. Learn more.
Focus on: RNA-based therapies PERSPECTIVES Top OPINION Article series: RNA-based therapies Non-coding RNAs as drug targets Masayuki Matsui & David R. Corey p167 | doi:10.1038/nrd.2016.117 Non-coding RNAs (ncRNAs) may affect normal gene expression and disease progression, thereby representing potential drug targets. Here, Matsui and Corey assess the potential and challenges in therapeutically exploiting ncRNA species — including microRNA, intronic RNA, repetitive RNA and long ncRNA — highlighting key lessons learned during the development of technologies targeting mRNA. Abstract | Full Text | PDF
Advertisement
Poster on effects of new antidiabetic drugs on cardiovascular health This poster summarizes cardiovascular outcome trials of newly developed glucose-lowering agents. Some of these drugs have shown cardiovascular benefit that might have clinical importance in the management of type 2 diabetes.  Available to download  Supported by an educational grant from Novo Nordisk
Focus on: RNA-based therapies REVIEWS Top Article series: RNA-based therapies Aptamers as targeted therapeutics: current potential and challenges Jiehua Zhou & John Rossi p181 | doi:10.1038/nrd.2016.199 Nucleic acid aptamers offer several advantages over traditional antibodies, but their clinical translation has been delayed by several factors, including insufficient potency, lack of safety data and high production costs. Here, Zhou and Rossi provide an overview of aptamer generation, focusing on recent technological advances and clinical development, as well as challenges and lessons learned. Abstract | Full Text | PDF Article series: RNA-based therapies MicroRNA therapeutics: towards a new era for the management of cancer and other diseases Rajesha Rupaimoole & Frank J. Slack p203 | doi:10.1038/nrd.2016.246 MicroRNAs (miRNAs) are small non-coding RNAs that can modulate mRNA expression. Insights into the roles of miRNAs in development and disease have led to the development of new therapeutic approaches that are based on miRNA mimics or agents that inhibit their functions (antimiRs), and the first such approaches have entered the clinic. This Review discusses the role of different miRNAs in cancer and other diseases, and provides an overview of current miRNA therapeutics in the clinic. Abstract | Full Text | PDF | Supplementary information
Advertisement
npj Systems Biology and Applications - Open for Submissions A new open access, multi- and interdisciplinary journal dedicated to publishing the highest quality papers on systems biology, the journal is now open for submissions. Explore the benefits of submitting your next research.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.